PT  - JOURNAL ARTICLE
AU  - Xia Liu
AU  - Li Ma
AU  - Jinhui Tian
AU  - Kehu Yang
TI  - Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
AID  - 10.1007/s11805-009-0412-4
DP  - 2009 Dec 01
TA  - Clinical Oncology and Cancer Research
PG  - 412--417
VI  - 6
IP  - 6
4099  - http://www.cancerbiomed.org/content/6/6/412.short
4100  - http://www.cancerbiomed.org/content/6/6/412.full
SO  - Cancer Biol Med2009 Dec 01; 6
AB  - OBJECTIVE To evaluate the efficacy and adverse effects of gemcitabine versus pegylated liposomal doxorubicin in patients with progressive or recurrent ovarian cancer.METHODS We conducted a systematic literature search to identify all randomized controlled trials comparing gemcitabine and pegylated liposomal doxorubicin for progressive or recurrent ovarian cancer. Trial data were reviewed and extracted independently by 2 reviewers. We evaluated the quality of the included studies using the Handbook 5.0 recommend standards and then analyzed data by Cochrane Collaboration’s RevMan 5.0.RESULTS Two trials which included a total of 348 patients were analyzed. The results of meta-analysis showed that gemcitabine improved disease control rates significantly bett er than pegylated liposomal doxorubicin. A greater number of patients receiving gemcitabine experienced neutropenia compared with patients receiving pegylated liposomal doxorubicin; however, hand-foot syndrome and mucositis were more severe in patients receiving pegylated liposomal doxorubicin.CONCLUSION Gemcitabine provided a limited advantage compared with pegylated liposomal doxorubicin. There exists an urgent need for more high-quality, multicenter, adequate randomized, controlled clinical trials for comparing gemcitabine with pegylated liposomal doxorubicin in patients with progressive/recurrent ovarian cancer.